English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Artificial Intelligence in Mammography-Based Breast Cancer Screening

Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusNot yet recruiting
Sponsors
Chinese University of Hong Kong
Collaborators
IBM China/Hong Kong Limited

Keywords

Abstract

Breast cancer (BC) is the most common cancer among women in worldwide and the second leading cause of cancer-related death.
As the corner stone of BC screening, mammography is recognized as one of useful imaging modalities to reduce BC mortality, by virtue of early detection of BC. However, mammography interpretation is inherently subjective assessment, and prone to overdiagnosis.
In recent years, artificial intelligence (AI)-Computer Aided Diagnosis (CAD) systems, characterized by embedded deep-learning algorithms, have entered into the field of BC screening as an aid for radiologist, with purpose to optimize conventional CAD system with weakness of hand-crafted features extraction. For now, stand-alone performance of novel AI-CAD tools have demonstrated promising accuracy and efficiency in BC diagnosis, largely attributed to utilization of convolution neural network(CNNs), and some of them have already achieved radiologist-like level. On the other hand, radiologists' performance on BC screening has shown to be enhanced, by leveraging AI-CAD system as decision support tool. As increasing implementation of commercial AI-CAD system, robust evaluation of its usefulness and cost-effectiveness in clinical circumstances should be undertaken in scenarios mimicking real life before broad adoption, like other emerging and promising technologies. This requires to validate AI-CAD systems in BC screening on multiple, diverse and representative datasets and also to estimate the interface between reader and system. This proposed study seeks to investigate the breast cancer diagnostic performance of AI-CAD system used for reading mammograms. In this work, we will employ a commercially available AI-CAD tool based on deep-learning algorithms (IBM Watson Imaging AI Solution) to identify and characterize the suspicious breast lesions on mammograms. The potential cancer lesions can be labeled and their mammographic features and malignancy probability will be automatically reported. After AI post-processing, we shall further carry out statistical analysis to determine the accuracy of AI-CAD system for BC risk prediction.

Dates

Last Verified: 06/30/2020
First Submitted: 11/05/2019
Estimated Enrollment Submitted: 11/05/2019
First Posted: 11/07/2019
Last Update Submitted: 07/13/2020
Last Update Posted: 07/15/2020
Actual Study Start Date: 07/31/2020
Estimated Primary Completion Date: 11/30/2023
Estimated Study Completion Date: 05/31/2024

Condition or disease

Breast Cancer

Intervention/treatment

Other: mammography

Phase

-

Eligibility Criteria

Sexes Eligible for StudyFemale
Sampling methodProbability Sample
Accepts Healthy VolunteersYes
Criteria

Inclusion Criteria:

- Women who had undergone standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views..

- Histopathology-proven diagnosis is available for patients with breast malignancy, including invasive breast cancer, carcinoma in situ, and borderline lesion et al.

- As reference standard of benign nature, results from pathology or clinical long-term follow-up (>=2 years) examinations are available for cases without breast malignancy.

Exclusion Criteria:

- Patients with concurring lesions on mammograms that may influence subsequent AI post-process.

- Patients without available pathologic diagnosis or long-term follow-up (>=2 years) examinations.

- Patients who had undergone breast surgical intervention (e.g. lumpectomy and mammoplasty) prior to first mammography.

- Patients diagnosed with other kinds of malignancy, concurrent with metastasis or infiltration/invasion to breast.

Outcome

Primary Outcome Measures

1. area under curve (AUC) [3 years]

area under receiver operating characteristic (ROC) curve in percentage (%)

2. accuracy [3 years]

proportion of true results(both true positives and true negatives) among whole instances

3. sensitivity [3 years]

true positive rate in percentage(%) derived by ROC analysis

4. specificity [3 years]

true negative rate in percentage (%) derived by ROC analysis

Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge